Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Haemolytic anemia due to glutathione reductase (GSR) deficiency is characterized by nearly complete absence of GSR activity in erythrocytes.
Features include always present findings: Cataract and Reduced erythrocyte glutathione reductase activity. 4 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 1 | Cataract |
Lab test results |
GSR encodes glutathione-disulfide reductase (522 aa). Catalyzes the reduction of glutathione disulfide (GSSG) to reduced glutathione (GSH). Constitutes the major mechanism to maintain a high GSH:GSSG ratio in the cytosol Highest expression in Cells Cultured fibroblasts (68.0 TPM) and Cells EBV-transformed lymphocytes (64.8 TPM).
Hemolytic anemia due to glutathione reductase deficiency is associated with mutations in the GSR gene on chromosome 8.
The GSR protein participates in GSR gene:p-NFE2L2, NFE2L2-dependent GSR gene expression, and GSSeSG is reduced to GSSeH and GSH by GSR pathways.
GSR is classified as a druggable target (Druggable Genome, Enzyme, and External Side Of Plasma Membrane categories) with score 2.4.
Genetic testing for GSR is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for hemolytic anemia due to glutathione reductase deficiency.
3 publications have been identified in PubMed for hemolytic anemia due to glutathione reductase deficiency. Research spans Other (33%), Case Report / Case Series (33%), and Basic Science / Preclinical (33%).
Lucbert A (2026). [PMID: 41883493](https://pubmed.ncbi.nlm.nih.gov/41883493/). *Pract Lab Med*. [Case Report / Case Series]
Roy S (2026). [PMID: 41984322](https://pubmed.ncbi.nlm.nih.gov/41984322/). *Indian Pediatr*. [Other]
Valenzuela-Villatoro M (2025). [PMID: 40333285](https://pubmed.ncbi.nlm.nih.gov/40333285/). *G3 (Bethesda, Md.)*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 5:10 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1
Hyperbilirubinemia |
Blood and immune system | 1 | Fava bean-induced hemolytic anemia |
Age of onset: adulthood.